07/12/2018 02:49:48

Viveve Announces Pricing of Public Offering of Shares of Common Stock

ENGLEWOOD, Colo., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The gross proceeds to Viveve from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Viveve, are expected to be $20.0 million. All shares of common stock are being offered by Viveve.

In addition, Viveve has granted the underwriters a 30-day option to purchase up to an additional 1,999,999 shares of common stock at the public offering price. The offering is expected to close on or about December 11, 2018, subject to the satisfaction of customary closing conditions. Viveve intends to use the net proceeds from this offering to support the continued commercialization of its products in North America and internationally, to obtain additional regulatory clearances and to conduct the VIVEVE II Sexual Function and LIBERATE – International and LIBERATE – U.S. stress urinary incontinence (SUI) clinical trials, and for general corporate and working capital purposes.

Cowen is acting as sole book-running manager of the offering. Raymond James is acting as lead manager for the offering. Mizuho Securities is acting as co-manager for the offering.

This announcement shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The securities described above are being offered by Viveve pursuant to Viveve’s registration statements on Form S-3 (File Nos. 333-221432 and 333-213682) previously filed and declared effective by the U.S. Securities and Exchange Commission (the “SEC”).

The offering will be made only by means of a prospectus supplement and accompanying prospectuses. A final prospectus supplement and accompanying prospectuses relating to and describing the terms of this offering will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying prospectuses can be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by email at PostSaleManualRequests@broadridge.com, or by accessing the SEC’s website, www.sec.gov.

About Viveve

Viveve Medical, Inc. is a women’s intimate health company committed to advancing new solutions to improve women’s overall well-being and quality of life. The internationally patented Viveve® System, that delivers the Viveve treatment, incorporates cryogen-cooled, monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session.

International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in over 50 countries. In the second quarter of 2018, Viveve initiated VIVEVE II, a multicenter, randomized, double-blind, sham-controlled clinical trial to assess improvement of sexual function in women following vaginal childbirth after receiving approval of an Investigational Device Exemption (IDE) application from the U.S. Food and Drug Administration (FDA) in March of 2018. If successful, this trial could support a marketing application for a new U.S. commercial indication. Currently, in the United States, the Viveve System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis.

Viveve has initiated LIBERATE-International, one of two planned independent, multicenter, randomized registration trials for the improvement of SUI in women and plans to re-submit an IDE to the FDA for LIBERATE-U.S., after conducting certain safety testing in the third quarter of 2019. The results of these two trials, if successful, could support marketing applications in the U.S. and additional countries around the world for this new commercial indication.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, our anticipated public offering, future expectations, plans and prospects for us, and the timing of these events, along with those risks set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, and the prospectus supplement related to the public offering, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the SEC, which are or will be available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Viveve is a registered trademark of Viveve, Inc.

Investor Relations contacts:

Sarah McCabe

Stern Investor Relations, Inc.

(212) 362-1200

sarah@sternir.com

Amato and Partners, LLC

Investor Relations Counsel

admin@amatoandpartners.com

Media contact

Kelly Wakelee

Berry & Company Public Relations 

(212) 253-8881

kwakelee@berrypr.com

viv_logo_1c_cmyk_noR.jpg

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
11 Dec
 
mne: Short - når det lykkedes!    Forbyd short totalt. - Det er kursmanipulatorernes og finansforbr..
67
10 Dec
VELO
Når man følger Veloxis-debatten, og det hr jeg gjort i mange, mange år - også da den hed LCP, så går..
31
08 Dec
VELO
Havde igår en lang snak med min kapitalforvalter emnet - hvordan er det gået Hr og Fru Danmark's por..
27
13 Dec
PNDORA
"Carnegie bestemmer pandoras aktiekurs, basta!!Sådan udtaler en chefanalytiker sig.Carnegie har samm..
25
12 Dec
PNDORA
Stornedtur: Din profil er da lige oprettet for 6 dage siden 😎 er du en troll/bandit 😂 Stornedtur A..
22
13 Dec
DANSKE
CBS undersøgte muligheden for at droppe Danske Bank helt: Vi skal fare med lempe Kilde: https://fina..
16
12 Dec
VWS
Vestas opruster i teknologisk kapløb om fremtidens vindmølle. Vestas skruer op for investeringer i n..
16
10 Dec
 
Klart, klart... et firma, der reklamerer må være desperat. Personligt synes jeg ikke Pandora har n..
16
13 Dec
PNDORA
Din skrivelse er intet andet end en omgang sludder. Det rene nonsens. Det er simpelthen ubegribelig..
15
12 Dec
VELO
  Der er som jeg ser det, kun et forhold, som kan sænke kursen betydeligt, og det er en yderligere u..
15

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Megaputer Adds Support for a 16th Language in its Advanced Text Analysis Software
2
Teligent, Inc. Executes $120 Million Financing Agreement
3
LGI Homes Opens Three New Communities in Greater Raleigh
4
The Jewelry Exchange launches TrueRadiant™ line of Lab Grown Jewelry at $499 per carat
5
Bragar Eagel & Squire, P.C. is Investigating Yangtze River Port and Logistics Limited (YRIV) on Behalf of Stockholders and Encourages YRIV Investors to Contact the Firm

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
14 December 2018 13:16:35
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181207.1 - EUROWEB6 - 2018-12-14 14:16:35 - 2018-12-14 13:16:35 - 1000 - Website: OKAY